TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) 100/25 mcg Once Daily Compared With Vilanterol Inhalation Powder (VI) 25 mcg Once Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: This is a Phase IIIa, multicenter, randomized, stratified (reversibility status), double-blind, parallel-group study to evaluate the efficacy and safety of FF/VI 100/25 micrograms (mcg) once daily (QD) compared with VI 25 mcg QD, administered in the morning via the ELLIPTA™ inhaler. The primary objective of this study is to evaluate the contribution on lung function (as measured by trough forced expiratory volume in one second \[FEV1\]) of FF 100 mcg to the FF/VI 100/25 mcg QD combination by comparison of the latter with VI 25 mcg QD and the safety of FF/VI 100/25 mcg over a 12-week treatment period in subjects with COPD. ELLIPTA™ is a registered trademark of GlaxoSmithKline.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Budesonide/formoterol (Symbicort Turbuhaler) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol (Oxis Turbuhaler) | Intervention Type: DRUG; Name: Budesonide/formoterol (Symbicort Turbuhaler); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Formoterol (Oxis Turbuhaler); Assigned to Arm(s): 2
B: Arm Label: Umeclidinium/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium/Vilanterol 62.5/25 mcg | Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 mcg | Intervention Type: DRUG; Name: Umeclidinium/Vilanterol 62.5/25 mcg; Assigned to Arm(s): Umeclidinium/Vilanterol | Intervention Type: DRUG; Name: Tiotropium 18 mcg; Assigned to Arm(s): Tiotropium
C: Arm Label: FF/GW642444 Inhalation Powder 100/25 mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Powder 200/25 mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Powder 50mcg/25mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: GW642444 25mcg QD; Type: EXPERIMENTAL; Interventions: Drug: GW642444 Inhalation Powder | Intervention Type: DRUG; Name: FF/GW642444 Inhalation Powder; Assigned to Arm(s): FF/GW642444 Inhalation Powder 100/25 mcg QD, FF/GW642444 Inhalation Powder 200/25 mcg QD, FF/GW642444 Inhalation Powder 50mcg/25mcg QD | Intervention Type: DRUG; Name: GW642444 Inhalation Powder; Assigned to Arm(s): GW642444 25mcg QD
D: Arm Label: Fluticasone Furoate/Vilanterol 100/25 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/Vilanterol | Arm Label: Vilanterol 25 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: Vilanterol | Intervention Type: DRUG; Name: Fluticasone Furoate/Vilanterol; Assigned to Arm(s): Fluticasone Furoate/Vilanterol 100/25 Inhalation Powder | Intervention Type: DRUG; Name: Vilanterol; Assigned to Arm(s): Vilanterol 25 Inhalation Powder

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early In-hospital Initiation of Pharmacotherapy for Smoking Cessation, Concomitant With Nurse-Led Support, in Patients After an Acute Coronary Syndrome (ACS)
Brief Summary: The hypothesis of this study is that combination of Varenicline treatment with nurse-led hospital support during hospitalization and after discharge will result in clinically significant higher long term abstinence rates in smokers with ACS, as compared with nurse led support and placebo, without a significant increase in the risk of adverse events.


Options:
A: Arm Label: study groups; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): study groups | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): control group
B: Arm Label: Varenicline and Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline and Placebo Patch | Arm Label: Varenicline and Nicotine Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Nicotine Patch | Intervention Type: DRUG; Name: Varenicline, Nicotine Patch; Assigned to Arm(s): Varenicline and Nicotine Patch | Intervention Type: DRUG; Name: Varenicline and Placebo Patch; Assigned to Arm(s): Varenicline and Placebo Patch
C: Arm Label: Nicotine-inclusive e-cigarettes; Type: EXPERIMENTAL; Interventions: Other: Electronic Cigarette and behavioural change support. | Arm Label: Nicotine-free e-cigarettes; Type: EXPERIMENTAL; Interventions: Other: Nicotine-Free Electronic Cigarette and behavioural change support. | Arm Label: Nicotine Replacement Therapy (NRT); Type: ACTIVE_COMPARATOR; Interventions: Other: Nicotine Replacement Therapy and behavioural change support. | Intervention Type: OTHER; Name: Electronic Cigarette and behavioural change support.; Assigned to Arm(s): Nicotine-inclusive e-cigarettes | Intervention Type: OTHER; Name: Nicotine-Free Electronic Cigarette and behavioural change support.; Assigned to Arm(s): Nicotine-free e-cigarettes | Intervention Type: OTHER; Name: Nicotine Replacement Therapy and behavioural change support.; Assigned to Arm(s): Nicotine Replacement Therapy (NRT)
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early In-hospital Initiation of Pharmacotherapy for Smoking Cessation, Concomitant With Nurse-Led Support, in Patients After an Acute Coronary Syndrome (ACS)
Brief Summary: The hypothesis of this study is that combination of Varenicline treatment with nurse-led hospital support during hospitalization and after discharge will result in clinically significant higher long term abstinence rates in smokers with ACS, as compared with nurse led support and placebo, without a significant increase in the risk of adverse events.


Options:
A: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Nicotine Patches only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches | Arm Label: Nicotine Patches with Nicotine Inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, Drug: Nicotine Inhaler | Arm Label: varenicline with bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline, varenicline with bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): varenicline with bupropion | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Nicotine Patches only, Nicotine Patches with Nicotine Inhaler | Intervention Type: DRUG; Name: Nicotine Inhaler; Assigned to Arm(s): Nicotine Patches with Nicotine Inhaler
B: Arm Label: study groups; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): study groups | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): control group
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Varenicline Tartrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Varenicline Tartrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early In-hospital Initiation of Pharmacotherapy for Smoking Cessation, Concomitant With Nurse-Led Support, in Patients After an Acute Coronary Syndrome (ACS)
Brief Summary: The hypothesis of this study is that combination of Varenicline treatment with nurse-led hospital support during hospitalization and after discharge will result in clinically significant higher long term abstinence rates in smokers with ACS, as compared with nurse led support and placebo, without a significant increase in the risk of adverse events.


Options:
A: Arm Label: study groups; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): study groups | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): control group
B: Arm Label: E-Cigarette; Type: EXPERIMENTAL; Interventions: Behavioral: E-cigarette | Arm Label: Assessments only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: E-cigarette; Assigned to Arm(s): E-Cigarette
C: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early In-hospital Initiation of Pharmacotherapy for Smoking Cessation, Concomitant With Nurse-Led Support, in Patients After an Acute Coronary Syndrome (ACS)
Brief Summary: The hypothesis of this study is that combination of Varenicline treatment with nurse-led hospital support during hospitalization and after discharge will result in clinically significant higher long term abstinence rates in smokers with ACS, as compared with nurse led support and placebo, without a significant increase in the risk of adverse events.


Options:
A: Arm Label: 1: Bup+MM; Type: EXPERIMENTAL; Interventions: Drug: bupropion, Behavioral: Medication Management, Drug: placebo patch | Arm Label: 2 Bup+Mayo; Type: EXPERIMENTAL; Interventions: Drug: bupropion, Behavioral: Mayo Counseling, Drug: placebo patch | Arm Label: 3 Patch+MM; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine transdermal system, Behavioral: Medication Management, Drug: placebo bupropion | Arm Label: 4 Patch+Mayo; Type: EXPERIMENTAL; Interventions: Drug: nicotine transdermal system, Behavioral: Mayo Counseling, Drug: placebo bupropion | Intervention Type: DRUG; Name: nicotine transdermal system; Assigned to Arm(s): 3 Patch+MM, 4 Patch+Mayo | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): 1: Bup+MM, 2 Bup+Mayo | Intervention Type: BEHAVIORAL; Name: Medication Management; Assigned to Arm(s): 1: Bup+MM, 3 Patch+MM | Intervention Type: BEHAVIORAL; Name: Mayo Counseling; Assigned to Arm(s): 2 Bup+Mayo, 4 Patch+Mayo | Intervention Type: DRUG; Name: placebo patch; Assigned to Arm(s): 1: Bup+MM, 2 Bup+Mayo | Intervention Type: DRUG; Name: placebo bupropion; Assigned to Arm(s): 3 Patch+MM, 4 Patch+Mayo
B: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: study groups; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): study groups | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): control group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early In-hospital Initiation of Pharmacotherapy for Smoking Cessation, Concomitant With Nurse-Led Support, in Patients After an Acute Coronary Syndrome (ACS)
Brief Summary: The hypothesis of this study is that combination of Varenicline treatment with nurse-led hospital support during hospitalization and after discharge will result in clinically significant higher long term abstinence rates in smokers with ACS, as compared with nurse led support and placebo, without a significant increase in the risk of adverse events.


Options:
A: Arm Label: study groups; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): study groups | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): control group
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling and Nicotine replacement (CN) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling, Nicotine replacement and Bupropion (CNB) | Intervention Type: BEHAVIORAL; Name: Counseling and Nicotine replacement (CN); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Counseling, Nicotine replacement and Bupropion (CNB); Assigned to Arm(s): 3
C: Arm Label: Scheduled Gradual Reduction + Varenicline; Type: EXPERIMENTAL; Interventions: Other: Scheduled Gradual Reduction + Varenicline | Arm Label: Scheduled Gradual Reduction + Placebo Drug; Type: EXPERIMENTAL; Interventions: Other: Scheduled Gradual Reduction + Placebo Drug | Arm Label: Basic Advice + Varenicline; Type: EXPERIMENTAL; Interventions: Other: Basic Advice + Varenicline | Arm Label: Basic Advice + Placebo Drug; Type: PLACEBO_COMPARATOR; Interventions: Other: Basic Advice + Placebo Drug | Intervention Type: OTHER; Name: Scheduled Gradual Reduction + Varenicline; Assigned to Arm(s): Scheduled Gradual Reduction + Varenicline | Intervention Type: OTHER; Name: Scheduled Gradual Reduction + Placebo Drug; Assigned to Arm(s): Scheduled Gradual Reduction + Placebo Drug | Intervention Type: OTHER; Name: Basic Advice + Varenicline; Assigned to Arm(s): Basic Advice + Varenicline | Intervention Type: OTHER; Name: Basic Advice + Placebo Drug; Assigned to Arm(s): Basic Advice + Placebo Drug
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nicotine patch, nicotine inhaler, bupropion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch | Intervention Type: DRUG; Name: Nicotine patch, nicotine inhaler, bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nicotine patch; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early In-hospital Initiation of Pharmacotherapy for Smoking Cessation, Concomitant With Nurse-Led Support, in Patients After an Acute Coronary Syndrome (ACS)
Brief Summary: The hypothesis of this study is that combination of Varenicline treatment with nurse-led hospital support during hospitalization and after discharge will result in clinically significant higher long term abstinence rates in smokers with ACS, as compared with nurse led support and placebo, without a significant increase in the risk of adverse events.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pharmacotherapies for Smoking Cessation | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pharmacotherapies for Smoking Cessation | Intervention Type: DRUG; Name: Pharmacotherapies for Smoking Cessation; Assigned to Arm(s): 1, 2
C: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pil; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Sugar Pil
D: Arm Label: study groups; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): study groups | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): control group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early In-hospital Initiation of Pharmacotherapy for Smoking Cessation, Concomitant With Nurse-Led Support, in Patients After an Acute Coronary Syndrome (ACS)
Brief Summary: The hypothesis of this study is that combination of Varenicline treatment with nurse-led hospital support during hospitalization and after discharge will result in clinically significant higher long term abstinence rates in smokers with ACS, as compared with nurse led support and placebo, without a significant increase in the risk of adverse events.


Options:
A: Arm Label: study groups; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): study groups | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): control group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: nicotine patch | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: nicotine lozenge | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: nicotine patch + nicotine lozenge | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bupropion | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: bupropion + lozenge | Arm Label: 6; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine lozenge; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: nicotine patch + nicotine lozenge; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: bupropion + lozenge; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 6
C: Arm Label: patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine patch | Arm Label: nicotine lozenge; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine lozenge | Arm Label: bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion | Arm Label: patch + lozenge; Type: ACTIVE_COMPARATOR; Interventions: Drug: patch + lozenge | Arm Label: buproion + lozenge; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion + lozenge | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): patch | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): patch | Intervention Type: DRUG; Name: nicotine lozenge; Assigned to Arm(s): nicotine lozenge | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: patch + lozenge; Assigned to Arm(s): patch + lozenge | Intervention Type: DRUG; Name: bupropion + lozenge; Assigned to Arm(s): buproion + lozenge
D: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Behavioral: Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Counseling | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: BEHAVIORAL; Name: Counseling; Assigned to Arm(s): Placebo, Varenicline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Brief Summary: The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14 days over 48 weeks.


Options:
A: Arm Label: Ciprofloxacin DPI 28 Days on/off (Cipro 28); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Ciprofloxacin DPI 14 Days on/off (Cipro 14); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Placebo 28 Days on/off (Placebo 28); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo 14 Days on/off (Placebo 14); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin DPI (BAYQ3939); Assigned to Arm(s): Ciprofloxacin DPI 14 Days on/off (Cipro 14), Ciprofloxacin DPI 28 Days on/off (Cipro 28) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 14 Days on/off (Placebo 14), Placebo 28 Days on/off (Placebo 28)
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Mannitol | Arm Label: 2; Type: OTHER; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Gentamicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): 2
D: Arm Label: Ciprofloxacin DPI 28 Days on/off (Cipro 28); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (BAYQ3939) dry powder for inhalation | Arm Label: Ciprofloxacin DPI 14 Days on/off (Cipro 14); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (BAYQ3939) dry powder for inhalation | Arm Label: Placebo 28 Days on/off (Placebo 28); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo 14 Days on/off (Placebo 14); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin (BAYQ3939) dry powder for inhalation; Assigned to Arm(s): Ciprofloxacin DPI 28 Days on/off (Cipro 28) | Intervention Type: DRUG; Name: Ciprofloxacin (BAYQ3939) dry powder for inhalation; Assigned to Arm(s): Ciprofloxacin DPI 14 Days on/off (Cipro 14) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 28 Days on/off (Placebo 28) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 14 Days on/off (Placebo 14)

Answer: D